keyword
MENU ▼
Read by QxMD icon Read
search

Biochemical relapse of prostate cancer

keyword
https://www.readbyqxmd.com/read/29151782/salvage-low-dose-rate-brachytherapy-for-recurrent-prostate-cancer-after-external-beam-radiotherapy-results-from-a-single-institution-with-focus-on-toxicity-and-functional-outcomes
#1
F Barbera, L Triggiani, M Buglione, P Ghirardelli, P Vitali, B Caraffini, P Borghetti, D Greco, L Bardoscia, N Pasinetti, L Costa, M Maddalo, B Ghedi, B La Face, S M Magrini
Background/aim: Low dose rate brachytherapy has been used as salvage therapy for locally recurrent prostate cancer (PC) after primary external beam radiation therapy (EBRT), along with surgery and cryotherapy. All these techniques, in particular, when applied to the whole gland, involve a relatively high risk of toxicity and may worsen the patient's quality of life. Our aim is to evaluate the results of whole-gland salvage brachytherapy (SBT) after primary EBRT in terms of toxicity, functional outcomes, and efficacy...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29137875/contribution-of-11-c-choline-pet-ct-in-prostate-carcinoma-biochemical-relapse-with-serum-psa-level-below-1-ng-ml
#2
F J Gómez-de la Fuente, I Martínez-Rodríguez, M de Arcocha-Torres, R Quirce, J Jiménez-Bonilla, N Martínez-Amador, I Banzo
OBJECTIVE: (11)C-choline PET/CT has demonstrated good results in the restaging of prostate cancer (PCa) with high serum prostate specific antigen (PSA), but its use in patients with low serum PSA is controversial. Our aim was to evaluate the contribution of (11)C-choline PET/CT in patients with PCa, biochemical relapse and PSA <1 ng/ml. MATERIAL AND METHOD: Fifty consecutive patients (mean age: 65.9±5.6 years) with biochemical relapse of PCa and serum PSA <1ng/ml were evaluated retrospectively...
November 11, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29107276/managing-cancer-relapse-after-radical-prostatectomy-adjuvant-versus-salvage-radiation-therapy
#3
REVIEW
Joseph F Rodriguez, Stanley L Liauw, Scott E Eggener
An increasing proportion of men are undergoing radical prostatectomy for locally advanced prostate cancer. More than half of men with adverse pathologic features are expected to experience disease recurrence within 10 years. This article discusses the use of postoperative radiation therapy to decrease this risk. Evidence from 3 randomized trials and multiple retrospective studies indicates that either adjuvant or salvage radiation improve biochemical progression-free survival and may improve overall survival...
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29105797/-99m-tc-mip-1404-spect-ct-for-the-detection-of-psma-positive-lesions-in-225-patients-with-biochemical-recurrence-of-prostate-cancer
#4
Christian Schmidkonz, Claudia Hollweg, Michael Beck, Julia Reinfelder, Theresa I Goetz, James C Sanders, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Alexander Cavallaro, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: (99m) Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible (99m) Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse. METHODS: From April 2013 to April 2017, (99m) Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer...
November 6, 2017: Prostate
https://www.readbyqxmd.com/read/29045551/validation-of-a-metastatic-assay-using-biopsies-to-improve-risk-stratification-in-patients-with-prostate-cancer-treated-with-radical-radiation-therapy
#5
S Jain, C A Lyons, S M Walker, S McQuaid, S Hynes, D Mitchell, B Pang, G E Logan, A M McCavigan, D O'Rourke, D McArt, S McDade, I Mills, K M Prise, L A Knight, C J Steele, P W Medlow, V Berge, B Katz, D A Loblaw, D P Harkin, J James, J M O'Sullivan, R D Kennedy, D J Waugh
BackgroundRadiotherapy is an effective treatment for intermediate/high-risk locally-advanced prostate cancer, however, >30% of patients relapse within five years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy (ADT)...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29039785/prospective-comparison-of-f-18-choline-pet-ct-scan-versus-axial-mri-for-detecting-bone-metastasis-in-biochemically-relapsed-prostate-cancer-patients
#6
Wouter Huysse, Frédéric Lecouvet, Paolo Castellucci, Piet Ost, Valerie Lambrecht, Carlos Artigas, Marie-Laurence Denis, Kathia De Man, Louke Delrue, Lennart Jans, Aurélie De Bruycker, Filip De Vos, Gert De Meerleer, Karel Decaestecker, Valerie Fonteyne, Bieke Lambert
We compared fluor-18 choline positron emission tomography/computed tomography (PET/CT) and axial skeleton magnetic resonance imaging (MRI) prospectively obtained for the detection of bone metastases in non-castrated patients with biochemically recurrent prostate cancer following primary treatment. PET/CT was performed 45 min post-injection of 3-4 MBq/kg F-18 methyl choline. MRI included T1- and fluid sensitive T2-weighted images of the spine and pelvis. Readers were initially blinded from other results and all scans underwent independent double reading...
October 17, 2017: Diagnostics
https://www.readbyqxmd.com/read/29032014/high-intermediate-prostate-cancer-treated-with-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-therapy
#7
Tom Pickles, W James Morris, Mira Keyes
PURPOSE: To describe outcomes of men with unfavorable (high-tier) intermediate risk prostate cancer (H-IR) treated with low-dose-rate (LDR) brachytherapy, with or without 6 months of androgen deprivation therapy (ADT). METHODS AND MATERIALS: Patients with H-IR prostate cancer, treated before 2012 with LDR brachytherapy without external radiation are included. Baseline tumor characteristics are described. Outcomes between groups receiving ADT are measured by Phoenix (nadir +2 ng/mL), and threshold 0...
November 2017: Brachytherapy
https://www.readbyqxmd.com/read/28992050/clinical-outcomes-of-125i-brachytherapy-with-and-without-external-beam-radiation-therapy-for-localized-prostate-cancer-results-from-300-patients-at-a-single-institution-in-japan
#8
Sayo Maki, Yoshiyuki Itoh, Seiji Kubota, Tohru Okada, Rie Nakahara, Junji Ito, Mariko Kawamura, Shinji Naganawa, Yasushi Yoshino, Takashi Fujita, Masashi Kato, Momokazu Gotoh, Mitsuru Ikeda
The aim of this study was to determine the outcomes and adverse events for 300 men with prostate cancer treated with 125iodine (125I) brachytherapy with and without external-beam radiation therapy (EBRT) at a single institution in Japan. Between February 2005 and November 2011, 300 consecutive patients with clinically localized prostate cancer were treated with 125I brachytherapy at the Nagoya University Hospital. A total of 271 men were treated with implants with doses of 145 Gy, and 29 men were treated with implants with doses of 110 Gy combined with EBRT (40-50 Gy/20-25 fractions)...
September 12, 2017: Journal of Radiation Research
https://www.readbyqxmd.com/read/28984165/target-definition-in-salvage-postoperative-radiotherapy-for-prostate-cancer-18f-fluorocholine-pet-ct-assessment-of-local-recurrence
#9
Osman El Kabbaj, Philippe Robin, David Bourhis, Gurvan Dissaux, Nicola Rosenfelder, Antoine Valeri, Georges Fournier, Pierre-Yves Salaun, Olivier Pradier, Jean-Pierre Malhaire, Ronan Abgral, Ulrike Schick
PURPOSE: Inadequate clinical target volume (CTV) definition is likely to be a major contributing factor to local recurrence (LR) rate after radiotherapy. Our aims were to identify sites of prostate cancer LR in biochemical recurrence post-prostatectomy using (18)F-Fluorocholine (18F-FCH) positron emission tomography/computed tomography (PET/CT) and to compare different CTV-delineation guidelines in a cohort of postoperative patients. MATERIAL AND METHODS: Thirty-six patients presenting with LR within the prostatic bed on 18F-FCH PET/CT between 10/2011 and 06/2016 were included in this retrospective study...
October 6, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28982908/long-term-tumor-control-and-late-toxicity-in-patients-with-prostate-cancer-receiving-hypofractionated-2-2-gy-soft-tissue-matched-image-guided-intensity-modulated-radiotherapy
#10
Daisuke Shimizu, Hideya Yamazaki, Takuya Nishimura, Norihiro Aibe, Haruumi Okabe
AIM: We report the long-term tumor control and toxicity outcomes of patients undergoing hypofractionated (2.2 Gy) image-guided intensity-modulated radiotherapy (IG-IMRT) using tomotherapy for clinically localized prostate cancer. PATIENTS AND METHODS: We examined the cases of 138 consecutive patients with stage T1-T3 prostate cancer that were treated with IG-IMRT from June 2007 to July 2009. The median follow-up time was 79 months (range=31-96 months). The planning target volume received a dose of 72...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982907/hypofractionated-postoperative-imrt-in-prostate-carcinoma-a-phase-i-ii-study
#11
Gabriella Macchia, Giambattista Siepe, Ilaria Capocaccia, Nam P Nguyen, Riccardo Schiavina, Silvia Cammelli, Sara Guerri, Alessandra Arcelli, Milly Buwenge, Maria Ntreta, Savino Cilla, Vincenzo Valentini, Francesco Deodato, Alessio G Morganti
AIM: To report the outcome of hypofractionated radiotherapy after radical prostatectomy (RP) for prostate cancer (PCa) using simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT). PATIENTS AND METHODS: A total of 124 patients with PCa at high risk of relapse after RP or diagnosis of biochemical relapse were included. Patients received 62.5 Gy to the prostate bed and 45 Gy to pelvic nodes in 25 fractions. Androgen-suppressive therapy was prescribed based on National Comprehensive Cancer Network risk categories...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28982844/clinical-potential-of-statins-in-prostate-cancer-radiation-therapy
#12
REVIEW
Jack Hutchinson, Laure Marignol
BACKGROUND/AIM: Statins are cholesterol- lowering drugs that have been shown to possess anti-tumour properties. Observational studies have shown that 3-hydroxy-3-methlyglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced prostate cancer risk. Preclinical studies suggest that statins possess anticancer and radiosensitising properties. This review aims to determine the impact of statin use in the efficacy of radiation therapy and the therapeutic window in prostate cancer...
October 2017: Anticancer Research
https://www.readbyqxmd.com/read/28973396/incidental-prostate-cancer-in-patients-with-muscle-invasive-bladder-cancer-who-underwent-radical-cystoprostatectomy
#13
Toshikazu Tanaka, Takuya Koie, Chikara Ohyama, Yasuhiro Hashimoto, Atsushi Imai, Yuki Tobisawa, Shingo Hatakeyama, Hayato Yamamoto, Tohru Yoneyama, Hirotaka Horiguchi, Hirotake Kodama, Takahiro Yoneyama
Objectives: The aim of this study was to analyze the features of incidentally detected prostate cancer (PCa) in radical cystoprostatectomy (RCP) specimens to determine their pathological characteristics and clinical significance. Methods: In this retrospective study, we reviewed the clinical and pathological records of 431 consecutive patients with muscle-invasive bladder cancer who underwent RCP at Hirosaki University. Of these, we focused on 237 male patients with prostate-specific antigen (PSA) measurements and digital rectal examinations (DRE) that were recorded prior to the RCP...
November 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28945760/appraising-the-relevance-of-dna-copy-number-loss-and-gain-in-prostate-cancer-using-whole-genome-dna-sequence-data
#14
Niedzica Camacho, Peter Van Loo, Sandra Edwards, Jonathan D Kay, Lucy Matthews, Kerstin Haase, Jeremy Clark, Nening Dennis, Sarah Thomas, Barbara Kremeyer, Jorge Zamora, Adam P Butler, Gunes Gundem, Sue Merson, Hayley Luxton, Steve Hawkins, Mohammed Ghori, Luke Marsden, Adam Lambert, Katalin Karaszi, Gill Pelvender, Charlie E Massie, Zsofia Kote-Jarai, Keiran Raine, David Jones, William J Howat, Steven Hazell, Naomi Livni, Cyril Fisher, Christopher Ogden, Pardeep Kumar, Alan Thompson, David Nicol, Erik Mayer, Tim Dudderidge, Yongwei Yu, Hongwei Zhang, Nimish C Shah, Vincent J Gnanapragasam, William Isaacs, Tapio Visakorpi, Freddie Hamdy, Dan Berney, Clare Verrill, Anne Y Warren, David C Wedge, Andrew G Lynch, Christopher S Foster, Yong Jie Lu, G Steven Bova, Hayley C Whitaker, Ultan McDermott, David E Neal, Rosalind Eeles, Colin S Cooper, Daniel S Brewer
A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. 64 recurrent regions of loss and gain were detected, of which 28 were novel, including regions of loss with more than 15% frequency at Chr4p15.2-p15.1 (15.53%), Chr6q27 (16.50%) and Chr18q12...
September 2017: PLoS Genetics
https://www.readbyqxmd.com/read/28933270/11c-choline-pet-ct-based-helical-tomotherapy-as-treatment-approach-for-bone-metastases-in-recurrent-prostate-cancer-patients
#15
Elena Incerti, Vincenzo Gangemi, Paola Mapelli, Chiara Lucrezia Deantoni, Giampiero Giovacchini, Federico Fallanca, Andrei Fodor, Andrea Ciarmiello, Sergio Baldari, Luigi Gianolli, Nadia Di Muzio, Maria Picchio
To evaluate the efficacy of 11C-choline PET/CT (CHO-PET/CT) based helical tomotherapy (HTT) as a therapeutic approach for bone metastases in recurrent prostate cancer (PCa) patients. METHODS This retrospective study includes 20 PCa patients (median age: 67; range: 51-80 years) presenting biochemical relapse after primary treatment who underwent CHO-PET/CT based HTT on positive bone metastases from December 2007 to June 2014. The effectiveness of HTT assessed with biochemical response at 3/6/12 months, biochemical relapse free survival (bRFS) and overall survival (OS) at 2 years...
September 19, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28924967/postoperative-radiotherapy-for-prostate-cancer-the-sooner-the-better-and-potential-to-reduce-toxicity-even-further
#16
Paolo Borghetti, Luigi Spiazzi, Claudia Cozzaglio, Sara Pedretti, Bruno Caraffini, Luca Triggiani, Diana Greco, Lilia Bardoscia, Fernando Barbera, Michela Buglione, Stefano Maria Magrini
PURPOSE: To evaluate biochemical relapse-free survival (bRFS), overall survival (OS), late rectal and bladder toxicities in a retrospective single institution series, also applying an in-house software for biological dose calculation. METHODS: 258 patients submitted to radiotherapy after prostatectomy were considered. Differences between groups were calculated using the log-rank test and the relevant clinical and therapeutic variables were considered for multivariate analysis...
September 18, 2017: La Radiologia Medica
https://www.readbyqxmd.com/read/28894899/clinical-impact-of-psma-based-18-f-dcfbc-pet-ct-imaging-in-patients-with-biochemically-recurrent-prostate-cancer-after-primary-local-therapy
#17
Esther Mena, Maria L Lindenberg, Joanna H Shih, Stephen Adler, Stephanie Harmon, Ethan Bergvall, Deborah Citrin, William Dahut, Anita T Ton, Yolanda McKinney, Juanita Weaver, Philip Eclarinal, Alicia Forest, George Afari, Sibaprasad Bhattacharyya, Ronnie C Mease, Maria J Merino, Peter Pinto, Bradford J Wood, Paula Jacobs, Martin G Pomper, Peter L Choyke, Baris Turkbey
PURPOSE: The purpose of our study was to assess (18)F-DCFBC PET/CT, a PSMA targeted PET agent, for lesion detection and clinical management of biochemical relapse in prostate cancer patients after primary treatment. METHODS: This is a prospective IRB-approved study of 68 patients with documented biochemical recurrence after primary local therapy consisting of radical prostatectomy (n = 50), post radiation therapy (n = 9) or both (n = 9), with negative conventional imaging...
September 11, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28890088/management-of-local-relapse-after-prostate-cancer-radiotherapy-surgery-or-radiotherapy
#18
REVIEW
C Hennequin, J-M Hannoun-Lévi, F Rozet
Isolated local relapse after prostate cancer radiotherapy corresponds to 40% of biochemical failure. The management of these relapses is not well defined. Several strategies are available including surgery, high-intensity focused ultrasounds (HIFU), cryotherapy and reirradiation. Radical prostatectomy is the historical approach; biochemical control is obtained in 50 to 80% at 5 year. However, morbidity is higher after irradiation than as a first line treatment. Some limited series of HIFU and cryotherapy have been published with interesting results, but again the risk of urinary and rectal toxicity is high...
October 2017: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
https://www.readbyqxmd.com/read/28887398/-64-cucl2-pet-ct-in-prostate-cancer-relapse
#19
Arnoldo Piccardo, Francesco Paparo, Matteo Puntoni, Sergio Righi, Gianluca Bottoni, Lorenzo Bacigalupo, Silvia Zanardi, Andrea DeCensi, Giulia Ferrarazzo, Monica Gambaro, Filippo Grillo Ruggieri, Fabio Campodonico, Laura Tomasello, Luca Timossi, Simona Sola, Egesta Lopci, Manlio Cabria
To evaluate the biodistribution, kinetics and radiation dosimetry of (64)CuCl2 in humans and to assess the ability of (64)CuCl2-PoPET/CT to detect prostate cancer (PCa) recurrence in patients with biochemical relapse. Methods: we prospectively evaluated 50 PCa patients with biochemical relapse after surgery or external-beam radiation therapy. All patients underwent (64)CuCl2-PET/CT, (18)F-Choline-PET/CT and multiparametric magnetic resonance imaging (mpMRI) within 15 days of each other. Experienced readers interpreted the images, and the detection rate (DR) of each imaging modality was calculated...
September 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28882327/erectile-function-and-oncologic-outcomes-following-open-retropubic-and-robot-assisted-radical-prostatectomy-results-from-the-laparoscopic-prostatectomy-robot-open-trial
#20
Prasanna Sooriakumaran, Giovanni Pini, Tommy Nyberg, Maryam Derogar, Stefan Carlsson, Johan Stranne, Anders Bjartell, Jonas Hugosson, Gunnar Steineck, Peter N Wiklund
BACKGROUND: Whether surgeons perform better utilising a robot-assisted laparoscopic technique compared with an open approach during prostate cancer surgery is debatable. OBJECTIVE: To report erectile function and early oncologic outcomes for both surgical modalities, stratified by prostate cancer risk grouping. DESIGN, SETTING, AND PARTICIPANTS: In a prospective nonrandomised trial, we recruited 2545 men with prostate cancer from seven open (n=753) and seven robot-assisted (n=1792) Swedish centres (2008-2011)...
September 4, 2017: European Urology
keyword
keyword
111181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"